Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline and Rivaroxaban in Mild COVID-19
NCT04715295Phase 4Unknown
- Sponsor
- Yaoundé Central Hospital
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of doxycycline, rivaroxaban in coronavirus disease 2019 (COVID-19), sponsored by Yaoundé Central Hospital. Status: unknown.
02
Drugs
doxycyclinerivaroxaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04715295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04715295.